Uptake of pneumococcal vaccines in older Australian adults before and after universal public funding of PCV13
CONCLUSIONS: Changes in uptake of PCV13 and PPV23 among those aged 70 + years were consistent with program changes. However, PCV13 uptake was still substantially lower in individuals aged 65-69 years overall and in those with comorbidities.PMID:38584056 | DOI:10.1016/j.vaccine.2024.04.012 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Fariha Binte Hossain David Muscatello Sanjay Jayasinghe Jitendra Jonnagaddala Bette Liu Source Type: research
Uptake of pneumococcal vaccines in older Australian adults before and after universal public funding of PCV13
CONCLUSIONS: Changes in uptake of PCV13 and PPV23 among those aged 70 + years were consistent with program changes. However, PCV13 uptake was still substantially lower in individuals aged 65-69 years overall and in those with comorbidities.PMID:38584056 | DOI:10.1016/j.vaccine.2024.04.012 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Fariha Binte Hossain David Muscatello Sanjay Jayasinghe Jitendra Jonnagaddala Bette Liu Source Type: research
Factors associated with meningitis vaccine awareness and engagement among Latino men who have sex with men in South Florida
AbstractAwareness and uptake of the meningitis vaccine remains low among marginalized groups, such as Latino men who have sex with men (LMSM), potentially due to structural and psychosocial barriers in accessing preventative healthcare. The current study explored awareness and uptake of meningitis vaccines among a group of LMSM (N = 99) living in South Florida. A three-pronged variable selection approach was utilized prior to conducting regression models (linear and logistic). Overall, 48.5% of the participants reported little to no knowledge about meningitis vaccines, and 20.2% reported being vaccinated. Living with H...
Source: Journal of Behavioral Medicine - April 6, 2024 Category: Psychiatry Source Type: research
Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13
CONCLUSIONS: A PCV20 catch-up program could prevent pneumococcal infections, antibiotic prescriptions and antimicrobial-resistant infections and would be cost saving in the US.PMID:38577742 | DOI:10.1080/13696998.2024.2339638 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 5, 2024 Category: Health Management Authors: Mark H Rozenbaum Liping Huang Alejandro Cane Adriano Arguedas Ruth Chapman Desmond Dillon-Murphy Maria Tort Vincenza Snow Erica Chilson Raymond Farkouh Source Type: research
Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older
This study assesses the cost-effectiveness of PCV21 in US adults aged 50 years or older compared with currently recommended pneumococcal vaccines, from both the societal and healthcare perspectives. A Markov model evaluated the lifetime cost-effectiveness of PCV21 (given at age 50 years only, at ages 50/65 years, and risk-based at ages < 65 years plus age-based at age 65 years) compared to no vaccination and to currently recommended pneumococcal vaccines given either as currently recommended or routinely at ages 50/65 years. The analysis was conducted in hypothetical Black and non-Black cohorts aged 50 years or older, w...
Source: Vaccine - April 5, 2024 Category: Allergy & Immunology Authors: Shoroq M Altawalbeh Angela R Wateska Mary Patricia Nowalk Chyongchiou J Lin Lee H Harrison William Schaffner Richard K Zimmerman Kenneth J Smith Source Type: research
Ruxolitinib associated psoas muscle tuberculosis abscess in a primary myelofibrosis woman: A case report and literature review
Medicine (Baltimore). 2024 Apr 5;103(14):e37653. doi: 10.1097/MD.0000000000037653.ABSTRACTRATIONALE: Primary myelofibrosis is a subtype of myeloproliferative neoplasm that leads to bone marrow fibrosis. Historically, the only curative option for primary myelofibrosis was allogeneic hematopoietic stem cell transplant. Ruxolitinib, a Janus kinase inhibitor, is now used for the treatment of primary myelofibrosis and polycythemia vera. It effectively improves symptoms related to splenomegaly and anemia. However, its association with the development of opportunistic infections has been observed in clinical studies and practical...
Source: Herpes - April 5, 2024 Category: Infectious Diseases Authors: Chi-Yu Chen Tun-Chieh Chen Source Type: research
Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13
CONCLUSIONS: A PCV20 catch-up program could prevent pneumococcal infections, antibiotic prescriptions and antimicrobial-resistant infections and would be cost saving in the US.PMID:38577742 | DOI:10.1080/13696998.2024.2339638 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 5, 2024 Category: Health Management Authors: Mark H Rozenbaum Liping Huang Alejandro Cane Adriano Arguedas Ruth Chapman Desmond Dillon-Murphy Maria Tort Vincenza Snow Erica Chilson Raymond Farkouh Source Type: research
Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older
This study assesses the cost-effectiveness of PCV21 in US adults aged 50 years or older compared with currently recommended pneumococcal vaccines, from both the societal and healthcare perspectives. A Markov model evaluated the lifetime cost-effectiveness of PCV21 (given at age 50 years only, at ages 50/65 years, and risk-based at ages < 65 years plus age-based at age 65 years) compared to no vaccination and to currently recommended pneumococcal vaccines given either as currently recommended or routinely at ages 50/65 years. The analysis was conducted in hypothetical Black and non-Black cohorts aged 50 years or older, w...
Source: Vaccine - April 5, 2024 Category: Allergy & Immunology Authors: Shoroq M Altawalbeh Angela R Wateska Mary Patricia Nowalk Chyongchiou J Lin Lee H Harrison William Schaffner Richard K Zimmerman Kenneth J Smith Source Type: research
Retrospective study on the health and economic burden of hospitalized patients due to pneumonia and invasive pneumococcal infections in Belgium settings
CONCLUSION: Streptococcus pneumoniae infections remain a public health problem with significant cost for the Health Insurance and poor prognosis. Invasive pneumococcal infections are associated with longer hospital stays and required more intensive care than all other causes of pneumonia, in addition to be more costly, which justifies more attention for vaccination. This study also suggests an increase of economic and health burden with age and presence of underlying conditions.PMID:38575434 | DOI:10.1016/j.vaccine.2024.03.057 (Source: Vaccine)
Source: Vaccine - April 4, 2024 Category: Allergy & Immunology Authors: Pirson Magali Marbaix Sophie Bruyneel Arnaud Leclercq Pol Van Den Bulcke Julie Brauner Jonathan Source Type: research
Retrospective study on the health and economic burden of hospitalized patients due to pneumonia and invasive pneumococcal infections in Belgium settings
CONCLUSION: Streptococcus pneumoniae infections remain a public health problem with significant cost for the Health Insurance and poor prognosis. Invasive pneumococcal infections are associated with longer hospital stays and required more intensive care than all other causes of pneumonia, in addition to be more costly, which justifies more attention for vaccination. This study also suggests an increase of economic and health burden with age and presence of underlying conditions.PMID:38575434 | DOI:10.1016/j.vaccine.2024.03.057 (Source: Vaccine)
Source: Vaccine - April 4, 2024 Category: Allergy & Immunology Authors: Pirson Magali Marbaix Sophie Bruyneel Arnaud Leclercq Pol Van Den Bulcke Julie Brauner Jonathan Source Type: research
Modelling the Public Health Impact of MenACWY and MenC Adolescent Vaccination Strategies in Germany
ConclusionThe results of this study demonstrate that implementing MenACWY vaccination for adolescents in Germany is likely to notably reduce IMD incidence and mortality across age groups. However, the introduction of MenC adolescent vaccination shows only limited impact. Considering the extensive healthcare resources typically required for IMD management, these findings suggest the potential for economic benefits associated with the adoption of MenACWY adolescent vaccination, warranting further cost-effectiveness analysis. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - April 4, 2024 Category: Infectious Diseases Source Type: research
Novel method for production and purification of untagged pneumococcal surface protein A from clade 1
Appl Microbiol Biotechnol. 2024 Apr 4;108(1):281. doi: 10.1007/s00253-024-13098-2.ABSTRACTStreptococcus pneumoniae can cause diseases with high mortality and morbidity. The licensed vaccines are based on capsular polysaccharides and induce antibodies with low cross reactivity, leading to restricted coverage of serotypes. For surpassing this limitation, new pneumococcal vaccines are needed for induction of broader protection. One important candidate is the pneumococcal surface protein A (PspA), which can be classified in 6 clades and 3 families. We have reported an efficient process for production and purification of untagg...
Source: Applied Microbiology and Biotechnology - April 3, 2024 Category: Microbiology Authors: Tasson da Costa Rodrigues Patricia Zorzete Eliane Namie Miyaji Viviane Maimoni Gon çalves Source Type: research
Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation
CONCLUSION: This study demonstrates that despite high PCV13 efficacy against experimental Spn6B carriage in young, healthy Malawian adults, robust vaccine-induced systemic and mucosal anti-Spn6B CPS binding antibodies did not directly relate to protection.PMID:38570270 | DOI:10.1016/j.vaccine.2024.03.055 (Source: Vaccine)
Source: Vaccine - April 3, 2024 Category: Allergy & Immunology Authors: G Tembo M Mayuni R Kamng'ona L Chimgoneko G Chiwala S Sichone B Galafa F Thole C Mkandawire A E Chirwa E Nsomba V Nkhoma C Ngoliwa N Toto L Makhaza A Muyaya E Kudowa M Y R Henrion D Dula B Morton T Chikaonda S B Gordon K C Jambo Source Type: research
Understanding healthcare providers ’ preferred attributes of pediatric pneumococcal conjugate vaccines in the United States
Volume 20, Issue 1, December 2024 . (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - April 3, 2024 Category: Allergy & Immunology Authors: Salini MohantyJui-Hua TsaiNing NingAna MartinezRishi P. VermaMarieke HeisenJessica WeaverKristen A. FeemsterBianca ChunThomas W. WeissJordana K Schmiera Merck Research Laboratories, Merck & Co. Inc, Rahway, NJ, USAb Evidence & Access, OPEN Health, Bethe Source Type: research
